Replimune Group Inc
For the period ended Dec 31, 2023. Filed Feb 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 8, 2024
REPL$23.28+4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
| Nine Months Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(160,719) | $(125,045) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 26,201 | 21,209 |
| Depreciation | 1,950 | 1,919 |
| Net amortization of premiums and discounts on short-term investments | (9,515) | (1,782) |
| Noncash interest expense | 786 | 235 |
| Unrealized foreign currency transaction (gains) losses | (1,307) | — |
| Changes in operating assets and liabilities: | ||
| Research and development incentives receivable | (1,249) | 812 |
| Prepaid expenses and other current assets | (2,211) | (396) |
| Operating lease, right-of-use-asset | 437 | 382 |
| Finance lease, right-of-use-asset | 1,821 | 1,821 |
| Accounts payable | (1,505) | 357 |
| Accrued expenses and other current liabilities | 6,123 | 5,625 |
| Operating lease liabilities | (433) | (391) |
| Other non-current liabilities | 320 | — |
| Net cash used in operating activities | (139,301) | (95,254) |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment and software capitalization | (3,922) | (2,019) |
| Purchase of short-term investments | (381,115) | (433,911) |
| Proceeds from sales and maturities of short-term investments | 459,037 | 316,180 |
| Net cash provided by investing activities | 74,000 | (119,750) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of underwriting fees and discounts | — | 150,102 |
| Proceeds from issuance of prefunded warrants to purchase common stock, net of underwriting fees and discounts | — | 92,778 |
| Proceeds from issuance of common stock through ATM sales, net of offering costs | — | 37,438 |
| Proceeds from long-term debt | 15,000 | 30,000 |
| Payment of debt issuance costs | — | (1,846) |
| Principal payment of finance lease obligation | (345) | (262) |
| Proceeds from exercise of stock options | 1,758 | 3,170 |
| Net cash provided by financing activities | 16,413 | 311,380 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (30) | 4,343 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (48,918) | 100,719 |
| Cash, cash equivalents and restricted cash at beginning of period | 148,226 | 107,584 |
| Cash, cash equivalents and restricted cash at end of period | $99,308 | $208,303 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid during the period for interest | 2,036 | — |
| Cash paid for income taxes | 300 | — |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Common stock issuance costs included in accrued expenses | — | 249 |
| Purchases of property and equipment included in accounts payable | 127 | 19 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.